InvestorsObserver
×
News Home

Is Oncolytics Biotech, Inc. (ONCY) The Right Choice in Biotechnology?

Friday, January 08, 2021 03:21 PM | InvestorsObserver Analysts

Mentioned in this article

Is Oncolytics Biotech, Inc. (ONCY) The Right Choice in Biotechnology?

The 63 rating InvestorsObserver gives to Oncolytics Biotech, Inc. (ONCY) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, ONCY’s 63 overall rating means the stock scores better than 63 percent of all stocks.

Overall Score - 63
ONCY has an Overall Score of 63. Find out what this means to you and get the rest of the rankings on ONCY!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

What's Happening With Oncolytics Biotech, Inc. Stock Today?

Oncolytics Biotech, Inc. (ONCY) stock is lower by -2.7% while the S&P 500 has gained 0.33% as of 3:18 PM on Friday, Jan 8. ONCY is lower by -$0.07 from the previous closing price of $2.60 on volume of 1,437,755 shares. Over the past year the S&P 500 has gained 16.55% while ONCY is lower by -36.75%. ONCY lost -$0.82 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Oncolytics Biotech, Inc. (ONCY) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App